nach oben

Translational Stroke Research

Erschienen in:

27.06.2017 | Review

Emerging Roles of Sirtuins in Ischemic Stroke

verfasst von: David T. She, Dong-Gyu Jo, Thiruma V. Arumugam

Erschienen in: Translational Stroke Research | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Ischemic stroke is one of the leading causes of death worldwide. It is characterized by a sudden disruption of blood flow to the brain causing cell death and damage, which will lead to neurological impairments. In the current state, only one drug is approved to be used in clinical setting and new therapies that confer ischemic neuroprotection are desperately needed. Several targets and pathways have been indicated to be neuroprotective in ischemic stroke, among which the sirtuin family of nicotinamide adenine dinucleotide (NAD⁺)-dependent deacetylases has emerged as important modulators of several processes in the normal physiology and pathological conditions such as stroke. Recent studies have identified some members of the sirtuin family are able to ameliorate the devastating consequences of ischemic stroke by conferring neuroprotection by means of reducing neuronal cell death, oxidative stress, and neuroinflammation whereas some sirtuins are found to be detrimental in the pathophysiology of ischemic stroke. This review summarizes implications of sirtuins in ischemic stroke and the experimental evidences that demonstrate the potential of sirtuin modulators as neuroprotective therapy for ischemic stroke.

Frye RA. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun. 1999;260(1):273–9. doi:10.1006/bbrc.1999.0897.PubMedCrossRef

Brachmann CB, Sherman JM, Devine SE, Cameron EE, Pillus L, Boeke JD. The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability. Genes Dev. 1995;9(23):2888–902. doi:10.1101/gad.9.23.2888.PubMedCrossRef

Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795–800. doi:10.1038/35001622.PubMedCrossRef

Landry J, Sutton A, Tafrov ST, Heller RC, Stebbins J, Pillus L, et al. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc Natl Acad Sci U S A. 2000;97(11):5807–11. doi:10.1073/pnas.110148297.PubMedPubMedCentralCrossRef

Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun. 2000;273(2):793–8. doi:10.1006/bbrc.2000.3000.PubMedCrossRef

North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+−dependent tubulin deacetylase. Mol Cell. 2003;11(2):437–44.PubMedCrossRef

Jin Q, Yan T, Ge X, Sun C, Shi X, Zhai Q. Cytoplasm-localized SIRT1 enhances apoptosis. J Cell Physiol. 2007;213(1):88–97. doi:10.1002/jcp.21091.PubMedCrossRef

North BJ, Verdin E. Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS One. 2007;2(8):e784. doi:10.1371/journal.pone.0000784.PubMedPubMedCentralCrossRef

Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell. 2005;16(10):4623–35. doi:10.1091/mbc.E05-01-0033.PubMedPubMedCentralCrossRef

10.

Yamakuchi M, Lowenstein CJ. MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle. 2009;8(5):712–5. doi:10.4161/cc.8.5.7753.PubMedCrossRef

11.

Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science. 2004;306(5704):2105–8. doi:10.1126/science.1101731.PubMedCrossRef

12.

Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell. 2005;123(3):437–48. doi:10.1016/j.cell.2005.08.011.PubMedCrossRef

13.

Wang F, Nguyen M, Qin FX-F, Tong Q. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell. 2007;6(4):505–14. doi:10.1111/j.1474-9726.2007.00304.x.PubMedCrossRef

14.

Kobayashi Y, Furukawa-Hibi Y, Chen C, Horio Y, Isobe K, Ikeda K, et al. SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int J Mol Med. 2005;16(2):237–43.PubMed

15.

Qiao L, Shao J. SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J Biol Chem. 2006;281(52):39915–24. doi:10.1074/jbc.M607215200.PubMedCrossRef

16.

Jing E, Gesta S, Kahn CR. SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab. 2007;6(2):105–14. doi:10.1016/j.cmet.2007.07.003.PubMedPubMedCentralCrossRef

17.

Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 2005;434(7029):113–8. doi:10.1038/nature03354.PubMedCrossRef

18.

Krishnan J, Danzer C, Simka T, Ukropec J, Walter KM, Kumpf S, et al. Dietary obesity-associated Hif1α activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD+ system. Genes Dev. 2012;26(3):259–70. doi:10.1101/gad.180406.111.PubMedPubMedCentralCrossRef

19.

Oellerich MF, Potente M. FOXOs and sirtuins in vascular growth, maintenance, and aging. Circ Res. 2012;110(9):1238–51. doi:10.1161/CIRCRESAHA.111.246488.PubMedCrossRef

20.

Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, Reinberg D. Human SirT1 interacts with Histone H1 and promotes formation of facultative heterochromatin. Mol Cell Elsevier. 2004;16(1):93–105. doi:10.1016/j.molcel.2004.08.031.CrossRef

21.

Dang W, Steffen KK, Perry R, Dorsey JA, Johnson FB, Shilatifard A, et al. Histone H4 lysine 16 acetylation regulates cellular lifespan. Nature. 2009;459(7248):802–7. doi:10.1038/nature08085.PubMedPubMedCentralCrossRef

22.

Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, et al. Negative control of p53 by Sir2α promotes cell survival under stress. Cell. Elsevier. 2001;107(2):137–48. doi:10.1016/S0092-8674(01)00524-4.

23.

Vaziri H, Dessain SK, Eaton EN, Imai S-I, Frye RA, Pandita TK, et al. hSIR2 SIRT1 functions as an NAD-dependent p53 Deacetylase. Cell Elsevier. 2001;107(2):149–59. doi:10.1016/S0092-8674(01)00527-X.

24.

Leker RR, Aharonowiz M, Greig NH, Ovadia H. The role of p53-induced apoptosis in cerebral ischemia: effects of the p53 inhibitor pifithrin alpha. Exp Neurol. 2004;187(2):478–86. doi:10.1016/j.expneurol.2004.01.030.PubMedCrossRef

25.

Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004;303(5666):2011–5. doi:10.1126/science.1094637.PubMedCrossRef

26.

van der Horst A, Tertoolen LGJ, de Vries-Smits LMM, Frye RA, Medema RH, Burgering BMT. FOXO4 is acetylated upon peroxide stress and Deacetylated by the longevity protein hSir2SIRT1. J Biol Chem. 2004;279(28):28873–9. doi:10.1074/jbc.M401138200.PubMedCrossRef

27.

Santo EE, Stroeken P, Sluis PV, Koster J, Versteeg R, Westerhout EM. FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma. Cancer Res. 2013;73(7):2189–98. doi:10.1158/0008-5472.CAN-12-3767.PubMedCrossRef

28.

Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 2005;24(50):7410–25. doi:10.1038/sj.onc.1209086.PubMedCrossRef

29.

Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003;17(3):590–603. doi:10.1038/sj.leu.2402824.PubMedCrossRef

30.

Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell. 2004;116(4):551–63.PubMedCrossRef

31.

Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev. 2003;24(1):78–90. doi:10.1210/er.2002-0012.PubMedCrossRef

32.

St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jäger S, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006;127(2):397–408. doi:10.1016/j.cell.2006.09.024.PubMedCrossRef

33.

Srivastava S, Haigis MC. Role of sirtuins and calorie restriction in neuroprotection: implications in Alzheimer’s and Parkinson’s diseases. Curr Pharm Des. 2011;17(31):3418–33. doi:10.2174/138161211798072526.PubMedCrossRef

34.

Jin J, Iakova P, Jiang Y, Medrano EE, Timchenko NA. The reduction of SIRT1 in livers of old mice leads to impaired body homeostasis and to inhibition of liver proliferation. Hepatology. 2011;54(3):989–98. doi:10.1002/hep.24471.PubMedPubMedCentralCrossRef

35.

Yang Y, Duan W, Li Y, Jin Z, Yan J, Yu S, et al. Novel role of silent information regulator 1 in myocardial ischemia. Circulation. 2013;128(20):2232–40. doi:10.1161/CIRCULATIONAHA.113.002480.PubMedCrossRef

36.

Perrod S, Cockell MM, Laroche T, Renauld H, Ducrest A-L, Bonnard C, et al. A cytosolic NAD-dependent deacetylase, Hst2p, can modulate nucleolar and telomeric silencing in yeast. EMBO J Oxford, UK: Oxford University Press. 2001;20(1–2):197–209. doi:10.1093/emboj/20.1.197.CrossRef

37.

Vaquero A, Scher MB, Lee DH, Sutton A, Cheng H-L, Alt FW, et al. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev. 2006;20(10):1256–61. doi:10.1101/gad.1412706.PubMedPubMedCentralCrossRef

38.

de Oliveira RM, Sarkander J, Kazantsev AG, Outeiro TF. SIRT2 as a therapeutic target for age-related disorders. Front Pharmacol. 2012;3:82. doi:10.3389/fphar.2012.00082.PubMedPubMedCentralCrossRef

39.

Beirowski B, Gustin J, Armour SM, Yamamoto H, Viader A, North BJ, et al. Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through polarity protein par-3/atypical protein kinase C (aPKC) signaling. Proc Natl Acad Sci U S A. 2011;108(43):E952–61. doi:10.1073/pnas.1104969108.PubMedPubMedCentralCrossRef

40.

Jiang W, Wang S, Xiao M, Lin Y, Zhou L, Lei Q, et al. Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. Mol Cell. 2011;43(1):33–44. doi:10.1016/j.molcel.2011.04.028.PubMedPubMedCentralCrossRef

41.

Hiratsuka M, Inoue T, Toda T, Kimura N, Shirayoshi Y, Kamitani H, et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun. 2003;309(3):558–66. doi:10.1016/j.bbrc.2003.08.029.PubMedCrossRef

42.

Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005;102(44):16013–8. doi:10.1073/pnas.0500090102.PubMedPubMedCentralCrossRef

43.

Kim H-S, Vassilopoulos A, Wang R-H, Lahusen T, Xiao Z, Xu X, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell. 2011;20(4):487–99. doi:10.1016/j.ccr.2011.09.004.PubMedPubMedCentralCrossRef

44.

Dan L, Klimenkova O, Klimiankou M, Klusman JH, van den Heuvel-Eibrink MM, Reinhardt D, et al. The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica. 2012;97(4):551–9. doi:10.3324/haematol.2011.055236.PubMedPubMedCentralCrossRef

45.

Xie XQ, Zhang P, Tian B, Chen XQ. Downregulation of NAD-dependent Deacetylase SIRT2 protects mouse brain against ischemic stroke. Mol Neurobiol. 2016; doi:10.1007/s12035-016-0173-z.

46.

Krey L, Lühder F, Kusch K, Czech-Zechmeister B, Könnecke B, Fleming Outeiro T, et al. Knockout of silent information regulator 2 (SIRT2) preserves neurological function after experimental stroke in mice. J Cereb Blood Flow Metab. 2015;35(12):2080–8. doi:10.1038/jcbfm.2015.178.PubMedPubMedCentralCrossRef

47.

Hallows WC, Lee S, Denu JM. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc Natl Acad Sci U S A. 2006;103(27):10230–5. doi:10.1073/pnas.0604392103.PubMedPubMedCentralCrossRef

48.

Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010;464(7285):121–5. doi:10.1038/nature08778.PubMedPubMedCentralCrossRef

49.

Schlicker C, Gertz M, Papatheodorou P, Kachholz B, Becker CFW, Steegborn C. Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. J Mol Biol. 2008;382(3):790–801. doi:10.1016/j.jmb.2008.07.048.PubMedCrossRef

50.

Shimazu T, Hirschey MD, Hua L, Dittenhafer-Reed KE, Schwer B, Lombard DB, et al. SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and regulates ketone body production. Cell Metab. 2010;12(6):654–61. doi:10.1016/j.cmet.2010.11.003.PubMedPubMedCentralCrossRef

51.

Qiu X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. 2010;12(6):662–7. doi:10.1016/j.cmet.2010.11.015.PubMedCrossRef

52.

Yu W, Dittenhafer-Reed KE, Denu JM. SIRT3 protein deacetylates isocitrate dehydrogenase 2 (IDH2) and regulates mitochondrial redox status. J Biol Chem. 2012;287(17):14078–86. doi:10.1074/jbc.M112.355206.PubMedPubMedCentralCrossRef

53.

Hafner AV, Dai J, Gomes AP, Xiao C-Y, Palmeira CM, Rosenzweig A, et al. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging (Albany NY). 2010;2(12):914–23. doi:10.18632/aging.100252.CrossRef

54.

Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ, et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell. 2006;126(5):941–54. doi:10.1016/j.cell.2006.06.057.PubMedCrossRef

55.

Jeong SM, Xiao C, Finley LWS, Lahusen T, Souza AL, Pierce K, et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell. 2013;23(4):450–63. doi:10.1016/j.ccr.2013.02.024.PubMedPubMedCentralCrossRef

56.

Laurent G, de Boer VCJ, Finley LWS, Sweeney M, Lu H, Schug TT, et al. SIRT4 represses peroxisome proliferator-activated receptor α activity to suppress hepatic fat oxidation. Mol Cell Biol. 2013;33(22):4552–61. doi:10.1128/MCB.00087-13.PubMedPubMedCentralCrossRef

57.

Nasrin N, Wu X, Fortier E, Feng Y. Bare’ OC, Chen S, et al. SIRT4 regulates fatty acid oxidation and mitochondrial gene expression in liver and muscle cells. J Biol Chem. 2010;285(42):31995–2002. doi:10.1074/jbc.M110.124164.PubMedPubMedCentralCrossRef

58.

Laurent G, German NJ, Saha AK, de Boer VCJ, Davies M, Koves TR, et al. SIRT4 coordinates the balance between lipid synthesis and catabolism by repressing malonyl CoA decarboxylase. Mol Cell. 2013;50(5):686–98. doi:10.1016/j.molcel.2013.05.012.PubMedPubMedCentralCrossRef

59.

Tao Y, Huang C, Huang Y, Hong L, Wang H, Zhou Z, et al. SIRT4 suppresses inflammatory responses in human umbilical vein endothelial cells. Cardiovasc Toxicol. 2015;15(3):217–23. doi:10.1007/s12012-014-9287-6.PubMedCrossRef

60.

Du J, Zhou Y, Su X, Yu JJ, Khan S, Jiang H, et al. Sirt5 is a NAD-dependent protein lysine Demalonylase and Desuccinylase. Science. 2011;334(6057):806–9. doi:10.1126/science.1207861.PubMedPubMedCentralCrossRef

61.

Peng C, Lu Z, Xie Z, Cheng Z, Chen Y, Tan M, et al. The first identification of lysine malonylation substrates and its regulatory enzyme. Mol Cell Proteomics. 2011;10(12):M111.012658. doi:10.1074/mcp.M111.012658.PubMedPubMedCentralCrossRef

62.

Nakagawa T, Lomb DJ, Haigis MC, Guarente L. SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell. 2009;137(3):560–70. doi:10.1016/j.cell.2009.02.026.PubMedPubMedCentralCrossRef

63.

Park J, Chen Y, Tishkoff DX, Peng C, Tan M, Dai L, et al. SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways. Mol Cell. 2013;50(6):919–30. doi:10.1016/j.molcel.2013.06.001.PubMedPubMedCentralCrossRef

64.

Liang F, Wang X, Ow SH, Chen W, Ong WC. Sirtuin 5 is anti-apoptotic and anti-oxidative in cultured SH-EP Neuroblastoma cells. Neurotox Res. 2016; doi:10.1007/s12640-016-9664-y.

65.

Polletta L, Vernucci E, Carnevale I, Arcangeli T, Rotili D, Palmerio S, et al. SIRT5 regulation of ammonia-induced autophagy and mitophagy. Autophagy. 2015;11(2):253–70. doi:10.1080/15548627.2015.1009778.PubMedPubMedCentralCrossRef

66.

Guedouari H, Daigle T, Scorrano L, Hebert-Chatelain E. Sirtuin 5 protects mitochondria from fragmentation and degradation during starvation. Biochim. Biophys. Acta - Mol. Cell Res. 2017;1864(1):169–76. doi:10.1016/j.bbamcr.2016.10.015.

67.

Michishita E, McCord RA, Berber E, Kioi M, Padilla-Nash H, Damian M, et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature. 2008;452(7186):492–6. doi:10.1038/nature06736.PubMedPubMedCentralCrossRef

68.

Michishita E, McCord RA, Boxer LD, Barber MF, Hong T, Gozani O, et al. Cell cycle-dependent deacetylation of telomeric histone H3 lysine K56 by human SIRT6. Cell Cycle. 2009;8(16):2664–6. doi:10.4161/cc.8.16.9367.PubMedPubMedCentralCrossRef

69.

Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell. 2006;124(2):315–29. doi:10.1016/j.cell.2005.11.044.PubMedCrossRef

70.

McCord RA, Michishita E, Hong T, Berber E, Boxer LD, Kusumoto R, et al. SIRT6 stabilizes DNA-dependent protein kinase at chromatin for DNA double-strand break repair. Aging (Albany NY). 2009;1(1):109–21. doi:10.18632/aging.100011.CrossRef

71.

Mao Z, Hine C, Tian X, Van Meter M, Au M, Vaidya A, et al. SIRT6 promotes DNA repair under stress by activating PARP1. Science. 2011;332(6036):1443–6. doi:10.1126/science.1202723.PubMedPubMedCentralCrossRef

72.

Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, Nahum L, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012;483(7388):218–21. doi:10.1038/nature10815.PubMedCrossRef

73.

Ford E, Voit R, Liszt G, Magin C, Grummt I, Guarente L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev. 2006;20(9):1075–80. doi:10.1101/gad.1399706.PubMedPubMedCentralCrossRef

74.

Vakhrusheva O, Smolka C, Gajawada P, Kostin S, Boettger T, Kubin T, et al. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res. 2008;102(6):703–10. doi:10.1161/CIRCRESAHA.107.164558.PubMedCrossRef

75.

Tsai Y-C, Greco TM, Boonmee A, Miteva Y, Cristea IM. Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription. Mol Cell Proteomics. 2012;11(5):60–76. doi:10.1074/mcp.A111.015156.PubMedCrossRef

76.

Barber MF, Michishita E, Xi Y, Tasselli L, Kioi M, Moqtaderi Z, et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature. 2012;487(7405):114–8. doi:10.1038/nature11043.PubMedPubMedCentral

77.

Sidorova-Darmos E, Wither RG, Shulyakova N, Fisher C, Ratnam M, Aarts M, et al. Differential expression of sirtuin family members in the developing, adult, and aged rat brain. Front Aging Neurosci. 2014;6:333. doi:10.3389/fnagi.2014.00333.PubMedPubMedCentralCrossRef

78.

Sakamoto J, Miura T, Shimamoto K, Horio Y. Predominant expression of Sir2alpha, an NAD-dependent histone deacetylase, in the embryonic mouse heart and brain. FEBS Lett. 2004;556(1–3):281–6.PubMedCrossRef

79.

Hisahara S, Chiba S, Matsumoto H, Tanno M, Yagi H, Shimohama S, et al. Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear translocation. Proc Natl Acad Sci U S A. 2008;105(40):15599–604. doi:10.1073/pnas.0800612105.PubMedPubMedCentralCrossRef

80.

Ramadori G, Lee CE, Bookout AL, Lee S, Williams KW, Anderson J, et al. Brain SIRT1: anatomical distribution and regulation by energy availability. J Neurosci. 2008;28(40):9989–96. doi:10.1523/JNEUROSCI.3257-08.2008.PubMedPubMedCentralCrossRef

81.

Prozorovski T, Schulze-Topphoff U, Glumm R, Baumgart J, Schröter F, Ninnemann O, et al. Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat Cell Biol. 2008;10(4):385–94. doi:10.1038/ncb1700.PubMedCrossRef

82.

Chen J, Zhou Y, Mueller-Steiner S, Chen L-F, Kwon H, Yi S, et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem. 2005;280(48):40364–74. doi:10.1074/jbc.M509329200.PubMedCrossRef

83.

Körner S, Böselt S, Thau N, Rath KJ, Dengler R, Petri S. Differential sirtuin expression patterns in amyotrophic lateral sclerosis (ALS) postmortem tissue: neuroprotective or neurotoxic properties of sirtuins in ALS? Neurodegener Dis. 2013;11(3):141–52. doi:10.1159/000338048.PubMedCrossRef

84.

Park HR, Kong KH, Yu BP, Mattson MP, Lee J. Resveratrol inhibits the proliferation of neural progenitor cells and hippocampal neurogenesis. J Biol Chem. 2012;287(51):42588–600. doi:10.1074/jbc.M112.406413.PubMedPubMedCentralCrossRef

85.

Ma C-Y, Yao M, Zhai Q, Jiao J, Yuan X, Poo M. SIRT1 suppresses self-renewal of adult hippocampal neural stem cells. Development. 2014;141(24):4697–709. doi:10.1242/dev.117937.PubMedCrossRef

86.

Michán S, Li Y, Chou MM-H, Parrella E, Ge H, Long JM, et al. SIRT1 is essential for normal cognitive function and synaptic plasticity. J Neurosci. 2010;30(29):9695–707. doi:10.1523/JNEUROSCI.0027-10.2010.PubMedPubMedCentralCrossRef

87.

Gao J, Wang W-Y, Mao Y-W, Gräff J, Guan J-S, Pan L, et al. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature. 2010;466(7310):1105–9. doi:10.1038/nature09271.PubMedPubMedCentralCrossRef

88.

Maxwell MM, Tomkinson EM, Nobles J, Wizeman JW, Amore AM, Quinti L, et al. The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS. Hum Mol Genet. 2011;20(20):3986–96. doi:10.1093/hmg/ddr326.PubMedPubMedCentralCrossRef

89.

Braidy N, Poljak A, Grant R, Jayasena T, Mansour H, Chan-Ling T, et al. Differential expression of sirtuins in the aging rat brain. Front Cell Neurosci. 2015;9:167. doi:10.3389/fncel.2015.00167.PubMedPubMedCentralCrossRef

90.

Oh CS, Lee E, Lee YS, Shin DH. SIRT2 protein expression in normal and aged rat brain. J Korean Geriatr Soc. 2012;16(1):27. doi:10.4235/jkgs.2012.16.1.27.CrossRef

91.

Suzuki K, Koike T. Resveratrol abolishes resistance to axonal degeneration in slow Wallerian degeneration (WldS) mice: activation of SIRT2, an NAD-dependent tubulin deacetylase. Biochem Biophys Res Commun. 2007;359(3):665–71. doi:10.1016/j.bbrc.2007.05.164.PubMedCrossRef

92.

Creppe C, Malinouskaya L, Volvert M-L, Gillard M, Close P, Malaise O, et al. Elongator controls the migration and differentiation of cortical neurons through acetylation of alpha-tubulin. Cell. 2009;136(3):551–64. doi:10.1016/j.cell.2008.11.043.PubMedCrossRef

93.

Ferreira A, Cáceres A. The expression of acetylated microtubules during axonal and dendritic growth in cerebellar macroneurons which develop in vitro. Brain Res Dev Brain Res. 1989;49(2):205–13.PubMedCrossRef

94.

Taylor DM, Balabadra U, Xiang Z, Woodman B, Meade S, Amore A, et al. A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. ACS Chem Biol. 2011;6(6):540–6. doi:10.1021/cb100376q.PubMedCrossRef

95.

Pais TF, Szegő ÉM, Marques O, Miller-Fleming L, Antas P, Guerreiro P, et al. The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation. EMBO J. 2013;32(19):2603–16. doi:10.1038/emboj.2013.200.PubMedPubMedCentralCrossRef

96.

Zeng L, Yang Y, Hu Y, Sun Y, Du Z, Xie Z, et al. Age-related decrease in the mitochondrial sirtuin deacetylase Sirt3 expression associated with ROS accumulation in the auditory cortex of the mimetic aging rat model. PLoS One. 2014;9(2):e88019. doi:10.1371/journal.pone.0088019.PubMedPubMedCentralCrossRef

97.

Di Loreto S, Falone S, D’Alessandro A, Santini S, Sebastiani P, Cacchio M, et al. Regular and moderate exercise initiated in middle age prevents age-related amyloidogenesis and preserves synaptic and neuroprotective signaling in mouse brain cortex. Exp Gerontol. 2014;57:57–65. doi:10.1016/j.exger.2014.05.006.PubMedCrossRef

98.

Song W, Song Y, Kincaid B, Bossy B, Bossy-Wetzel E. Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neurons: neuroprotection by SIRT3 and PGC-1α. Neurobiol Dis. 2013;51:72–81. doi:10.1016/j.nbd.2012.07.004.PubMedCrossRef

99.

Someya S, Yu W, Hallows WC, Xu J, Vann JM, Leeuwenburgh C, et al. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell. 2010;143(5):802–12. doi:10.1016/j.cell.2010.10.002.PubMedPubMedCentralCrossRef

100.

Cheng A, Yang Y, Zhou Y, Maharana C, Lu D, Peng W, et al. Mitochondrial SIRT3 mediates adaptive responses of neurons to exercise and metabolic and excitatory challenges. Cell Metab. 2016;23(1):128–42. doi:10.1016/j.cmet.2015.10.013.PubMedCrossRef

101.

Komlos D, Mann KD, Zhuo Y, Ricupero CL, Hart RP, Liu AY-C, et al. Glutamate dehydrogenase 1 and SIRT4 regulate glial development. Glia. 2013;61(3):394–408. doi:10.1002/glia.22442.PubMedCrossRef

102.

Rardin MJ, He W, Nishida Y, Newman JC, Carrico C, Danielson SR, et al. SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks. Cell Metab. 2013;18(6):920–33. doi:10.1016/j.cmet.2013.11.013.PubMedPubMedCentralCrossRef

103.

Favero G, Rezzani R, Rodella LF. Sirtuin 6 nuclear localization at cortical brain level of young diabetic mice: an immunohistochemical study. Acta Histochem. 2014;116(1):272–7. doi:10.1016/j.acthis.2013.08.006.PubMedCrossRef

104.

Schwer B, Schumacher B, Lombard DB, Xiao C, Kurtev MV, Gao J, et al. Neural sirtuin 6 (Sirt6) ablation attenuates somatic growth and causes obesity. Proc Natl Acad Sci U S A. 2010;107(50):21790–4. doi:10.1073/pnas.1016306107.PubMedPubMedCentralCrossRef

105.

Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet (London, England). 2012;380(9859):2095–128. doi:10.1016/S0140-6736(12)61728-0.CrossRef

106.

Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology. 2008;55(3):310–8. doi:10.1016/j.neuropharm.2008.01.005.PubMedPubMedCentralCrossRef

107.

Bansal S, Sangha KS, Khatri P. Drug treatment of acute ischemic stroke. Am J Cardiovasc Drugs. 2013;13(1):57–69. doi:10.1007/s40256-013-0007-6.PubMedCrossRef

108.

Lipton P. Ischemic cell death in brain neurons. Physiol Rev. 1999;79(4):1431–568.PubMed

109.

Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67(2):181–98. doi:10.1016/j.neuron.2010.07.002.PubMedPubMedCentralCrossRef

110.

Hernández-Jiménez M, Hurtado O, Cuartero MI, Ballesteros I, Moraga A, Pradillo JM, et al. Silent information regulator 1 protects the brain against cerebral ischemic damage. Stroke. 2013;44(8):2333–7. doi:10.1161/STROKEAHA.113.001715.PubMedCrossRef

111.

Hattori Y, Okamoto Y, Maki T, Yamamoto Y, Oishi N, Yamahara K, et al. Silent information regulator 2 homolog 1 counters cerebral hypoperfusion injury by deacetylating endothelial nitric oxide synthase. Stroke. 2014;45(11):3403–11. doi:10.1161/STROKEAHA.114.006265.PubMedCrossRef

112.

Hattori Y, Okamoto Y, Nagatsuka K, Takahashi R, Kalaria RN, Kinoshita M, et al. SIRT1 attenuates severe ischemic damage by preserving cerebral blood flow. Neuroreport. 2015;26(3):113–7. doi:10.1097/WNR.0000000000000308.PubMedCrossRef

113.

Wang T, Gu J, Wu P-F, Wang F, Xiong Z, Yang Y-J, et al. Protection by tetrahydroxystilbene glucoside against cerebral ischemia: involvement of JNK, SIRT1, and NF-kappaB pathways and inhibition of intracellular ROS/RNS generation. Free Radic Biol Med. 2009;47(3):229–40. doi:10.1016/j.freeradbiomed.2009.02.027.PubMedCrossRef

114.

Fu B, Zhang J, Zhang X, Zhang C, Li Y, Zhang Y, et al. Alpha-lipoic acid upregulates SIRT1-dependent PGC-1α expression and protects mouse brain against focal ischemia. Neuroscience. 2014;281:251–7. doi:10.1016/j.neuroscience.2014.09.058.PubMedCrossRef

115.

Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, Gerard RD, et al. Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science. 2009;324(5932):1289–93. doi:10.1126/science.1169956.PubMedCrossRef

116.

Lim J-H, Lee Y-M, Chun Y-S, Chen J, Kim J-E, Park J-W. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol Cell. 2010;38(6):864–78. doi:10.1016/j.molcel.2010.05.023.PubMedCrossRef

117.

Wang P, Xu T-Y, Guan Y-F, Tian W-W, Viollet B, Rui Y-C, et al. Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann Neurol. 2011;69(2):360–74. doi:10.1002/ana.22236.PubMedCrossRef

118.

Hu Q, Manaenko A, Bian H, Guo Z, Huang J-L, Guo Z-N, et al. Hyperbaric oxygen reduces infarction volume and hemorrhagic transformation through ATP/NAD(+)/Sirt1 pathway in Hyperglycemic middle cerebral artery occlusion rats. Stroke. 2017; doi:10.1161/STROKEAHA.116.015753.

119.

Guo J-M, Shu H, Wang L, Xu J-J, Niu X-C, Zhang L. SIRT1-dependent AMPK pathway in the protection of estrogen against ischemic brain injury. CNS Neurosci. Ther. 2017;23(4):360–9. doi:10.1111/cns.12686.PubMedCrossRef

120.

Nie H, Hong Y, Lu X, Zhang J, Chen H, Li Y, et al. SIRT2 mediates oxidative stress-induced apoptosis of differentiated PC12 cells. Neuroreport. 2014; doi:10.1097/WNR.0000000000000192.

121.

Wang Q, Li L, Li CY, Pei Z, Zhou M, Li N. SIRT3 protects cells from hypoxia via PGC-1α- and MnSOD-dependent pathways. Neuroscience. 2015;286:109–21. doi:10.1016/j.neuroscience.2014.11.045.PubMedCrossRef

122.

Yin J, Han P, Tang Z, Liu Q, Shi J. Sirtuin 3 mediates neuroprotection of ketones against ischemic stroke. J Cereb Blood Flow Metab. 2015;35(11):1783–9. doi:10.1038/jcbfm.2015.123.PubMedPubMedCentralCrossRef

123.

Jacobs KM, Pennington JD, Bisht KS, Aykin-Burns N, Kim H-S, Mishra M, et al. SIRT3 interacts with the daf-16 homolog FOXO3a in the mitochondria, as well as increases FOXO3a dependent gene expression. Int J Biol Sci. 2008;4(5):291–9. doi:10.7150/ijbs.4.291.PubMedPubMedCentralCrossRef

124.

Peserico A, Chiacchiera F, Grossi V, Matrone A, Latorre D, Simonatto M, et al. A novel AMPK-dependent FoxO3A-SIRT3 intramitochondrial complex sensing glucose levels. Cell Mol Life Sci. 2013;70(11):2015–29. doi:10.1007/s00018-012-1244-6.PubMedCrossRef

125.

Novgorodov SA, Riley CL, Keffler JA, Yu J, Kindy MS, Macklin WB, et al. SIRT3 Deacetylates Ceramide Synthases: IMPLICATIONS FOR MITOCHONDRIAL DYSFUNCTION AND BRAIN INJURY. J Biol Chem. 2016;291(4):1957–73. doi:10.1074/jbc.M115.668228.PubMedCrossRef

126.

Shih J, Liu L, Mason A, Higashimori H, Donmez G. Loss of SIRT4 decreases GLT-1-dependent glutamate uptake and increases sensitivity to kainic acid. J Neurochem. 2014;131(5):573–81. doi:10.1111/jnc.12942.PubMedCrossRef

127.

Chu K, Lee S-T, Sinn D-I, Ko S-Y, Kim E-H, Kim J-M, et al. Pharmacological induction of ischemic Tolerance by glutamate transporter-1 (EAAT2) Upregulation. Stroke. 2007;38(1):177–82. doi:10.1161/01.STR.0000252091.36912.65.PubMedCrossRef

128.

Weller ML, Stone IM, Goss A, Rau T, Rova C, Poulsen DJ. Selective overexpression of excitatory amino acid transporter 2 (EAAT2) in astrocytes enhances neuroprotection from moderate but not severe hypoxia-ischemia. Neuroscience. 2008;155(4):1204–11. doi:10.1016/j.neuroscience.2008.05.059.PubMedPubMedCentralCrossRef

129.

Harvey BK, Airavaara M, Hinzman J, Wires EM, Chiocco MJ, Howard DB, et al. Targeted over-expression of glutamate transporter 1 (GLT-1) reduces ischemic brain injury in a rat model of stroke. PLoS One. 2011;6(8):e22135. doi:10.1371/journal.pone.0022135.PubMedPubMedCentralCrossRef

130.

Morris-Blanco KC, Dave KR, Saul I, Koronowski KB, Stradecki HM, Perez-Pinzon MA. Protein Kinase C epsilon promotes cerebral ischemic Tolerance via Modulation of mitochondrial Sirt5. Sci Rep. 2016;6:29790. doi:10.1038/srep29790.PubMedPubMedCentralCrossRef

131.

Di Y, He Y-L, Zhao T, Huang X, Wu K-W, Liu S-H, et al. Methylene blue reduces acute cerebral ischemic injury via the induction of Mitophagy. Mol Med. 2015;21:420–9. doi:10.2119/molmed.2015.00038.PubMedPubMedCentralCrossRef

132.

Zhang X, Yan H, Yuan Y, Gao J, Shen Z, Cheng Y, et al. Cerebral ischemia-reperfusion-induced autophagy protects against neuronal injury by mitochondrial clearance. Autophagy. 2013;9(9):1321–33. doi:10.4161/auto.25132.PubMedCrossRef

133.

Zuo W, Zhang S, Xia C-Y, Guo X-F, He W-B, Chen N-H. Mitochondria autophagy is induced after hypoxic/ischemic stress in a Drp1 dependent manner: the role of inhibition of Drp1 in ischemic brain damage. Neuropharmacology. 2014;86:103–15. doi:10.1016/j.neuropharm.2014.07.002.PubMedCrossRef

134.

Shi R-Y, Zhu S-H, Li V, Gibson SB, Xu X-S, Kong J-M. BNIP3 interacting with LC3 triggers excessive mitophagy in delayed neuronal death in stroke. CNS Neurosci. Ther. 2014;20(12):1045–55. doi:10.1111/cns.12325.PubMedCrossRef

135.

Kumari S, Anderson L, Farmer S, Mehta SL, Li PA. Hyperglycemia alters mitochondrial fission and fusion proteins in mice subjected to cerebral ischemia and reperfusion. Transl Stroke Res. 2012;3(2):296–304. doi:10.1007/s12975-012-0158-9.PubMedPubMedCentralCrossRef

136.

Baek S-H, Noh AR, Kim K-A, Akram M, Shin Y-J, Kim E-S, et al. Modulation of mitochondrial function and autophagy mediates carnosine neuroprotection against ischemic brain damage. Stroke. 2014;45(8):2438–43. doi:10.1161/STROKEAHA.114.005183.PubMedPubMedCentralCrossRef

137.

Jin J, Albertz J, Guo Z, Peng Q, Rudow G, Troncoso JC, et al. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington’s disease. J Neurochem. 2013;125(3):410–9. doi:10.1111/jnc.12190.PubMedPubMedCentralCrossRef

138.

Dong C, Della-Morte D, Wang L, Cabral D, Beecham A, McClendon MS, et al. Association of the sirtuin and mitochondrial uncoupling protein genes with carotid plaque. PLoS One. 2011;6(11):e27157. doi:10.1371/journal.pone.0027157.PubMedPubMedCentralCrossRef

139.

Lee O-H, Kim J, Kim J-M, Lee H, Kim EH, Bae S-K, et al. Decreased expression of sirtuin 6 is associated with release of high mobility group box-1 after cerebral ischemia. Biochem Biophys Res Commun. 2013;438(2):388–94. doi:10.1016/j.bbrc.2013.07.085.PubMedCrossRef

140.

Hu Y, Li R, Yang H, Luo H, Chen Z. Sirtuin 6 is essential for sodium sulfide-mediated cytoprotective effect in ischemia/reperfusion-stimulated brain endothelial cells. J Stroke Cerebrovasc Dis. 2015;24(3):601–9. doi:10.1016/j.jstrokecerebrovasdis.2014.10.006.PubMedCrossRef

141.

Shao J, Yang X, Liu T, Zhang T, Xie QR, Xia W. Autophagy induction by SIRT6 is involved in oxidative stress-induced neuronal damage. Protein Cell. 2016;7(4):281–90. doi:10.1007/s13238-016-0257-6.PubMedPubMedCentralCrossRef

142.

Zhang S, Chen P, Huang Z, Hu X, Chen M, Hu S, et al. Sirt7 promotes gastric cancer growth and inhibits apoptosis by epigenetically inhibiting miR-34a. Sci Rep. 2015;5:9787. doi:10.1038/srep09787.PubMedPubMedCentralCrossRef

143.

Wong Y-H, Wu C-C, Lai H-Y, Jheng B-R, Weng H-Y, Chang T-H, et al. Identification of network-based biomarkers of cardioembolic stroke using a systems biology approach with time series data. BMC Syst Biol. 2015;9(Suppl 6):S4. doi:10.1186/1752-0509-9-S6-S4.PubMedPubMedCentralCrossRef

144.

Hubbi ME, Hu H. Kshitiz, Gilkes DM, Semenza GL. Sirtuin-7 inhibits the activity of hypoxia-inducible factors. J Biol Chem. 2013;288(29):20768–75. doi:10.1074/jbc.M113.476903.PubMedPubMedCentralCrossRef

145.

Raval AP, Dave KR, Pérez-Pinzón MA. Resveratrol mimics ischemic preconditioning in the brain. J Cereb Blood Flow Metab. 2006;26(9):1141–7. doi:10.1038/sj.jcbfm.9600262.PubMedCrossRef

146.

Yang Y, Jiang S, Dong Y, Fan C, Zhao L, Yang X, et al. Melatonin prevents cell death and mitochondrial dysfunction via a SIRT1-dependent mechanism during ischemic-stroke in mice. J Pineal Res. 2015;58(1):61–70. doi:10.1111/jpi.12193.PubMedCrossRef

147.

Dong W, Li N, Gao D, Zhen H, Zhang X, Li F. Resveratrol attenuates ischemic brain damage in the delayed phase after stroke and induces messenger RNA and protein express for angiogenic factors. J Vasc Surg. 2008;48(3):709–14. doi:10.1016/j.jvs.2008.04.007.PubMedCrossRef

148.

Koronowski KB, Dave KR, Saul I, Camarena V, Thompson JW, Neumann JT, et al. Resveratrol preconditioning induces a novel extended window of ischemic Tolerance in the mouse brain. Stroke. 2015;46(8):2293–8. doi:10.1161/STROKEAHA.115.009876.PubMedPubMedCentralCrossRef

149.

Zhu H, Wang Z, Zhu X, Wu X, Li E, Xu Y. Icariin protects against brain injury by enhancing SIRT1-dependent PGC-1alpha expression in experimental stroke. Neuropharmacology. 2010;59(1–2):70–6. doi:10.1016/j.neuropharm.2010.03.017.PubMedCrossRef

150.

Chen X, Wales P, Quinti L, Zuo F, Moniot S, Herisson F, et al. The sirtuin-2 inhibitor AK7 is neuroprotective in models of parkinson’s disease but not amyotrophic lateral sclerosis and cerebral ischemia. PLoS One. 2015;10(1):1–15. doi:10.1371/journal.pone.0116919.

151.

Narayan N, Lee IH, Borenstein R, Sun J, Wong R, Tong G, et al. The NAD-dependent deacetylase SIRT2 is required for programmed necrosis. Nature. 2012;492(7428):199–204. doi:10.1038/nature11700.PubMedCrossRef

152.

Newton K, Hildebrand JM, Shen Z, Rodriguez D, Alvarez-Diaz S, Petersen S, et al. Is SIRT2 required for necroptosis? Nature. 2014;506(7489):E4–6. doi:10.1038/nature13024.PubMedPubMedCentralCrossRef

153.

Wei L, Zhou Y, Dai Q, Qiao C, Zhao L, Hui H, et al. Oroxylin a induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma. Cell Death Dis. 2013;4:e601. doi:10.1038/cddis.2013.131.PubMedPubMedCentralCrossRef

154.

Huang W-H, Lee A-R, Yang C-H. Antioxidative and anti-inflammatory activities of polyhydroxyflavonoids of Scutellaria Baicalensis GEORGI. Biosci Biotechnol Biochem. 2006;70(10):2371–80. doi:10.1271/bbb.50698.PubMedCrossRef

155.

Kim DH, Jeon SJ, Son KH, Jung JW, Lee S, Yoon BH, et al. The ameliorating effect of oroxylin a on scopolamine-induced memory impairment in mice. Neurobiol Learn Mem. 2007;87(4):536–46. doi:10.1016/j.nlm.2006.11.005.PubMedCrossRef

156.

Jiwajinda S, Santisopasri V, Murakami A, Kim O-K, Kim HW, Ohigashi H. Suppressive effects of edible Thai plants on superoxide and nitric oxide generation. Asian Pac J Cancer Prev. 2002;3(3):215–23.PubMed

157.

Cardinale A, de Stefano MC, Mollinari C, Racaniello M, Garaci E, Merlo D. Biochemical characterization of sirtuin 6 in the brain and its involvement in oxidative stress response. Neurochem Res. 2015;40(1):59–69. doi:10.1007/s11064-014-1465-1.PubMedCrossRef

158.

Wang R, Tang Y, Feng B, Ye C, Fang L, Zhang L, et al. Changes in hippocampal synapses and learning-memory abilities in age-increasing rats and effects of tetrahydroxystilbene glucoside in aged rats. Neuroscience. 2007;149(4):739–46. doi:10.1016/j.neuroscience.2007.07.065.PubMedCrossRef

159.

Zhang L, Xing Y, Ye C-F, Ai H-X, Wei H-F, Li L. Learning-memory deficit with aging in APP transgenic mice of Alzheimer’s disease and intervention by using tetrahydroxystilbene glucoside. Behav Brain Res. 2006;173(2):246–54. doi:10.1016/j.bbr.2006.06.034.PubMedCrossRef

160.

Zhang X-S, Wu Q, Wu L-Y, Ye Z-N, Jiang T-W, Li W, et al. Sirtuin 1 activation protects against early brain injury after experimental subarachnoid hemorrhage in rats. Cell Death Dis. 2016;7(10):e2416. doi:10.1038/cddis.2016.292.PubMedPubMedCentralCrossRef

161.

Toklu HZ, Hakan T, Biber N, Solakoğlu S, Oğünç AV, Sener G. The protective effect of alpha lipoic acid against traumatic brain injury in rats. Free Radic Res. 2009;43(7):658–67. doi:10.1080/10715760902988843.PubMedCrossRef

162.

Chen Y-J, Zheng H-Y, Huang X-X, Han S-X, Zhang D-S, Ni J-Z, et al. Neuroprotective effects of Icariin on brain metabolism, mitochondrial functions, and cognition in triple-transgenic Alzheimer’s disease mice. CNS Neurosci Ther. 2016;22(1):63–73. doi:10.1111/cns.12473.PubMedCrossRef

163.

Cardinali DP, Brusco LI, Liberczuk C, Furio AM. The use of melatonin in Alzheimer’s disease. Neuro Endocrinol. Lett. 2002;23(Suppl 1):20–3.

164.

Zhao Y-N, Li W-F, Li F, Zhang Z, Dai Y-D, Xu A-L, et al. Resveratrol improves learning and memory in normally aged mice through microRNA-CREB pathway. Biochem Biophys Res Commun. 2013;435(4):597–602. doi:10.1016/j.bbrc.2013.05.025.

165.

Ho DJ, Calingasan NY, Wille E, Dumont M, Beal MF. Resveratrol protects against peripheral deficits in a mouse model of Huntington’s disease. Exp Neurol. 2010;225(1):74–84. doi:10.1016/j.expneurol.2010.05.006.PubMedCrossRef

166.

Gueguen C, Palmier B, Plotkine M, Marchand-Leroux C, Besson VC. Neurological and histological consequences induced by in vivo cerebral oxidative stress: evidence for beneficial effects of SRT1720, a sirtuin 1 activator, and sirtuin 1-mediated neuroprotective effects of poly(ADP-ribose) polymerase inhibition. PLoS One. 2014;9(2):e87367. doi:10.1371/journal.pone.0087367.PubMedPubMedCentralCrossRef

167.

Gräff J, Kahn M, Samiei A, Gao J, Ota KT, Rei D, et al. A dietary regimen of caloric restriction or pharmacological activation of SIRT1 to delay the onset of neurodegeneration. J Neurosci. 2013;33(21):8951–60. doi:10.1523/JNEUROSCI.5657-12.2013.PubMedPubMedCentralCrossRef

168.

Smith MR, Syed A, Lukacsovich T, Purcell J, Barbaro BA, Worthge SA, et al. A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington’s disease. Hum Mol Genet. 2014;23(11):2995–3007. doi:10.1093/hmg/ddu010.PubMedPubMedCentralCrossRef

169.

Liu D, Gharavi R, Pitta M, Gleichmann M, Mattson MP. Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons. NeuroMolecular Med. 2009;11(1):28–42. doi:10.1007/s12017-009-8058-1.PubMedPubMedCentralCrossRef

170.

Schulz JB, Henshaw DR, Matthews RT, Beal MF. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp Neurol. 1995;132(2):279–83.PubMedCrossRef

171.

Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, et al. Nicotinamide restores cognition in Alzheimer’s disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci. 2008;28(45):11500–10. doi:10.1523/JNEUROSCI.3203-08.2008.PubMedPubMedCentralCrossRef

172.

Zhou X-M, Zhang X, Zhang X-S, Zhuang Z, Li W, Sun Q, et al. SIRT1 inhibition by sirtinol aggravates brain edema after experimental subarachnoid hemorrhage. J Neurosci Res. 2014;92(6):714–22. doi:10.1002/jnr.23359.PubMedCrossRef

173.

Spires-Jones TL, Fox LM, Rozkalne A, Pitstick R, Carlson GA, Kazantsev AG. Inhibition of Sirtuin 2 with Sulfobenzoic acid derivative AK1 is non-toxic and potentially Neuroprotective in a mouse model of Frontotemporal dementia. Front Pharmacol. 2012;3:42. doi:10.3389/fphar.2012.00042.PubMedPubMedCentralCrossRef

174.

Luthi-Carter R, Taylor DM, Pallos J, Lambert E, Amore A, Parker A, et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci U S A. 2010;107(17):7927–32. doi:10.1073/pnas.1002924107.PubMedPubMedCentralCrossRef

175.

Chopra V, Quinti L, Kim J, Vollor L, Narayanan KL, Edgerly C, et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington’s disease mouse models. Cell Rep. 2012;2(6):1492–7. doi:10.1016/j.celrep.2012.11.001.PubMedPubMedCentralCrossRef

176.

Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson’s disease. Science. 2007;317(5837):516–9. doi:10.1126/science.1143780.PubMedCrossRef

177.

Kim DH, Jeon SJ, Son KH, Jung JW, Lee S, Yoon BH, et al. Effect of the flavonoid, oroxylin a, on transient cerebral hypoperfusion-induced memory impairment in mice. Pharmacol Biochem Behav. 2006;85(3):658–68. doi:10.1016/j.pbb.2006.10.025.PubMedCrossRef

Titel: Emerging Roles of Sirtuins in Ischemic Stroke
verfasst von: David T. She
Dong-Gyu Jo
Thiruma V. Arumugam
Publikationsdatum: 27.06.2017
Verlag: Springer US
Erschienen in: Translational Stroke Research / Ausgabe 5/2017
Print ISSN: 1868-4483
Elektronische ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-017-0544-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

In Vivo Molecular MRI of ICAM-1 Expression on Endothelium and Leukocytes from Subacute to Chronic Stages After Experimental Stroke

Alpha-7 Nicotinic Receptor Signaling Pathway Participates in the Neurogenesis Induced by ChAT-Positive Neurons in the Subventricular Zone

Diabetes Worsens Functional Outcomes in Young Female Rats: Comparison of Stroke Models, Tissue Plasminogen Activator Effects, and Sexes

Cytoprotective Drug-Tissue Plasminogen Activator Protease Interaction Assays: Screening of Two Novel Cytoprotective Chromones

PCMT1 Ameliorates Neuronal Apoptosis by Inhibiting the Activation of MST1 after Subarachnoid Hemorrhage in Rats